Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 2/2018

SUNITINIB, A VEGFR RECEPTOR TYROSINE KINASE INHIBITOR AND ITS THYROID EFFECTS

RALUCA-ALEXANDRA TRIFANESCU 1,2, OANA-GABRIELA TRIFANESCU 1,3*, ANDREI GOLDSTEIN 2, MARIANA PURICE 2, RODICA ANGHEL 1,3, CATALINA POIANA 1,2

1.“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, Sector 1, 020022, Bucharest, Romania
2.“C.I. Parhon” National Institute of Endocrinology, 34 - 38 Aviatorilor Avenue, Sector 1, 011863, Bucharest, Romania
3.“Al. Trestioreanu” Institute of Oncology, 252 Fundeni Street, Sector 2, 022328, Bucharest, Romania
*corresponding author: endoparhon@gmail.com

Download Full Article PDF

Thyroid dysfunction occurs in 14 - 85% of patients treated with sunitinib, a multitargeted tyrosine-kinase inhibitor. Twenty-nine patients (20 males/9 females) treated with sunitinib (median dose 50 mg/day, 4 weeks “on”, 2 weeks “off” treatment regimen) for metastatic renal cell carcinoma were diagnosed with sunitinib-induced thyroid dysfunction. Thyroid function tests (thyroid-stimulating hormone (TSH), free T4 (thyroxine)) were measured by chemiluminescence. Primary hypothyroidism was initially diagnosed in 25 patients (86.2%), while transient thyrotoxicosis occurred in 4 patients (13.8%), followed by persistent hypothyroidism. Median duration of sunitinib treatment till diagnosis of hypothyroidism was 7 months and of thyrotoxicosis of 6.5 months, respectively. Overt hypothyroidism (17/25 patients) prevailed over subclinical hypothyroidism (8/25 patients), while overt thyrotoxicosis occurred similarly with subclinical thyrotoxicosis (2/4 patients). Due to high prevalence of sunitinib-induced thyroid dysfunction, monitoring of thyroid function is recommended.